Shares of Danaher (NYSE: DHR) surged by 12.9% after the company reported third-quarter earnings that beat expectations. Core revenue grew by 3% and the adjusted operating profit margin was 27.9%. The company attributed the strong performance to its Danaher Business System and growth in the bioprocessing business, driven by research into biologics. Additionally, better-than-expected revenue in the diagnostics segment was driven by early purchases ahead of the respiratory season, benefiting from flu season preparations.

While the results were positive, the market reaction may have been too strong. Danaher’s preliminary guidance for 2026 forecasts core revenue growth of 3-6% and high-single-digit earnings growth. However, with the stock trading at almost 29 times estimated 2025 earnings, further significant growth may be limited. Investors should carefully consider these factors before investing in Danaher.

Read more at Nasdaq: Here’s Why Shares in Danaher Got Boosted Higher Today